AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8932888 — intervention group
Group type: COMPARATOR
Intervention: Control group (structured activities and informal support)
Number of subjects: 40
Study 1416128 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 5 mg
Number of subjects: 40
Study 1416128 — intervention group
Group type: COMPARATOR
Intervention: naloxone 0.2 mg
Number of subjects: 40
Study 3927165 — intervention group
Group type: EXPERIMENTAL
Intervention: No cost sharing (0% coinsurance)
Number of subjects: 3973
Study 3927165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower third of income distribution
Number of subjects: 3973
Study 3927165 — intervention group
Group type: COMPARATOR
Intervention: Cost sharing (25%, 50%, 95% coinsurance)
Number of subjects: 3973
Study 31576513 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg
Number of subjects: 192
Study 31576513 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (Control)
Number of subjects: 192
Study 28401771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative breast magnetic resonance imaging
Number of subjects: 100
Study 28401771 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative breast magnetic resonance imaging)
Number of subjects: 100
Study 27903341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (D group) - received a loading dose of 0.3 μg/kg followed by a continuous infusion of 0.2-0.4 μg·kg-1·min-1 of dexmedetomidine and sufentanil (0.1 μg/kg)
Number of subjects: 60
Study 27903341 — intervention group
Group type: COMPARATOR
Intervention: Propofol group (P group) - received sufentanil 0.1 μg/kg and propofol 1.5 mg/kg followed by a continuous infusion of 3-6 mg·kg-1·h-1 of propofol
Number of subjects: 60
Study 24990091 — intervention group
Group type: EXPERIMENTAL
Intervention: L100/H12.5
Number of subjects: 0
Study 24990091 — intervention group
Group type: COMPARATOR
Intervention: L100
Number of subjects: 0
Study 24990091 — intervention group
Group type: COMPARATOR
Intervention: L50/H12.5
Number of subjects: 0
Study 22048884 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK372475 (1-2 mg/d)
Number of subjects: 0
Study 22048884 — intervention group
Group type: COMPARATOR
Intervention: Active control (venlafaxine XR 150-225 mg/d)
Number of subjects: 0
Study 22048884 — intervention group
Group type: COMPARATOR
Intervention: Active control (paroxetine 20-30 mg/d)
Number of subjects: 0
Study 20532709 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized three-layer tablet of venlafaxine hydrochloride
Number of subjects: 0
Study 20532709 — intervention group
Group type: COMPARATOR
Intervention: Marketed extended release capsule of venlafaxine hydrochloride
Number of subjects: 0
Study 18622777 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about the first psychotic episode
Number of subjects: 37
Study 18622777 — intervention group
Group type: COMPARATOR
Intervention: Writing about time management
Number of subjects: 37
Study 17166333 — intervention group
Group type: EXPERIMENTAL
Intervention: epoetin delta 150 IU/kg and 300 IU/kg
Number of subjects: 0
Study 17166333 — intervention group
Group type: COMPARATOR
Intervention: epoetin delta 15 IU/kg
Number of subjects: 0
Study 17166333 — intervention group
Group type: COMPARATOR
Intervention: epoetin alfa 50 IU/kg
Number of subjects: 0
Study 12716662 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (S, P, M)
Number of subjects: 16
Study 12716662 — intervention group
Group type: COMPARATOR
Intervention: Unsaturated fatty acids (O, T, L)
Number of subjects: 16
Study 10981217 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment modalities for acute dislocation of the patella; specific treatments not detailed
Number of subjects: 0
Study 10981217 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment modalities for recurrent dislocation of the patella; specific treatments not detailed
Number of subjects: 0
Study 8766874 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) intravenous bolus of 50 IU/kg
Number of subjects: 72
Study 8766874 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH infusion
Number of subjects: 72
Study 8766874 — intervention group
Group type: EXPERIMENTAL
Intervention: Single LMWH subcutaneous injection of 3,075 IU
Number of subjects: 72
Study 8766874 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH regimens
Number of subjects: 72
Study 1435590 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel therapy at a daily dose of 25 mg/kg for 2 days
Number of subjects: 1599
Study 1435590 — intervention group
Group type: COMPARATOR
Intervention: Chloxilin, medamin, or praziquantel (other therapeutic schemes)
Number of subjects: 1599
Study 6376718 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug combination chemotherapy program with CCNU
Number of subjects: 417
Study 6376718 — intervention group
Group type: COMPARATOR
Intervention: Four-drug combination chemotherapy program with mechlorethamine
Number of subjects: 417
Study 6376718 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU-containing programs
Number of subjects: 417
Study 6376718 — intervention group
Group type: EXPERIMENTAL
Intervention: Age less than 40
Number of subjects: 417
Study 30202873 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-virion inactivated influenza vaccine
Number of subjects: 0
Study 30202873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28323291 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrogestan
Number of subjects: 111
Study 28323291 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8%
Number of subjects: 111
Study 25765835 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin supplementation (140 mg, thrice daily for 45 days)
Number of subjects: 40
Study 25765835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25765835 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin supplementation
Number of subjects: 40
Study 25159238 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 56
Study 22676069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (tailored action plan for high risk premises)
Number of subjects: 32
Study 22676069 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 19594090 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 157
Study 19594090 — intervention group
Group type: COMPARATOR
Intervention: gelatin
Number of subjects: 157
Study 17894651 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (low exposure category)
Number of subjects: 6301
Study 17894651 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (intermediate exposure category)
Number of subjects: 6301
Study 17894651 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (high exposure category)
Number of subjects: 6301
Study 17894651 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline exposure in North America)
Number of subjects: 6301
Study 15286137 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted analysis
Number of subjects: 0
Study 15286137 — intervention group
Group type: EXPERIMENTAL
Intervention: Unweighted analysis
Number of subjects: 0
Study 15286137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-effects model
Number of subjects: 0
Study 15286137 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-effects model
Number of subjects: 0
Study 15286137 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II analysis
Number of subjects: 0
Study 15286137 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III analysis
Number of subjects: 0
Study 11570639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psoriasis vulgaris (PV)
Number of subjects: 0
Study 11570639 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 9631665 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening SIRS
Number of subjects: 75
Study 9631665 — intervention group
Group type: COMPARATOR
Intervention: Original SIRS
Number of subjects: 75
Study 8141223 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (hematinic group, n = 53)
Number of subjects: 97
Study 8141223 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 97
Study 8141223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 8141223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematonic group
Number of subjects: 97
Study 3222676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 310
Study 3222676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 29794951 — intervention group
Group type: EXPERIMENTAL
Intervention: Veinlite PEDI
Number of subjects: 112
Study 29794951 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 112
Study 30005020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonucleotide ligation assay (OLA)
Number of subjects: 492
Study 28865713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 181
Study 28865713 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181
Study 28865713 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of depressive symptoms
Number of subjects: 181
Study 26528167 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 28
Study 26528167 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 23025273 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse meat consumption (2 portions of 175 g/week)
Number of subjects: 52
Study 21403548 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic transethmoidal approach (ETEA) combined with transconjunctival inferior fornix approach (TIFA)
Number of subjects: 59
Study 21403548 — intervention group
Group type: COMPARATOR
Intervention: Medial canthal incision (MCI) combined with TIFA
Number of subjects: 59
Study 19694038 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS-HC
Number of subjects: 311
Study 19694038 — intervention group
Group type: COMPARATOR
Intervention: NASC
Number of subjects: 311
Study 16802483 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml/kg Hartmann's solution
Number of subjects: 160
Study 16802483 — intervention group
Group type: COMPARATOR
Intervention: 15 ml/kg Hartmann's solution
Number of subjects: 160
Study 15370356 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 10928461 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg levonorgestrel + 30 microg ethinylestradiol
Number of subjects: 28
Study 10928461 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg desogestrel + 30 microg ethinylestradiol
Number of subjects: 28
Study 10928461 — intervention group
Group type: COMPARATOR
Intervention: desogestrel-containing OC
Number of subjects: 28
Study 10928461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OC types
Number of subjects: 28
Study 9054840 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily for 4 weeks)
Number of subjects: 0
Study 8416460 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group (2 L of water)
Number of subjects: 40
Study 8416460 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 mL of water)
Number of subjects: 40
Study 8416460 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group
Number of subjects: 40
Study 8416460 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 3519058 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (20 g)
Number of subjects: 6
Study 3519058 — intervention group
Group type: COMPARATOR
Intervention: No guar gum
Number of subjects: 6
Study 31005913 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal prebiotic maternal supplementation (galacto-oligosaccharide/inulin)
Number of subjects: 376
Study 31005913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 376
Study 28116761 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 1-hour nap opportunity
Number of subjects: 57
Study 28116761 — intervention group
Group type: COMPARATOR
Intervention: No nap (control group)
Number of subjects: 57
Study 24843115 — intervention group
Group type: EXPERIMENTAL
Intervention: New curriculum
Number of subjects: 9
Study 24112150 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smokers after 4-week smoking cessation
Number of subjects: 42
Study 24112150 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 42
Study 24112150 — intervention group
Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 42
Study 24112150 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smokers
Number of subjects: 42
Study 21520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance peginterferon treatment
Number of subjects: 1050
Study 21520194 — intervention group
Group type: COMPARATOR
Intervention: Patients with cirrhosis
Number of subjects: 1050
Study 21520194 — intervention group
Group type: COMPARATOR
Intervention: Patients with fibrosis
Number of subjects: 1050
Study 21520194 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP score≥7
Number of subjects: 1050
Study 21520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1050
Study 18637601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 26
Study 18637601 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (Control)
Number of subjects: 26
Study 16567825 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (anti-CD25)
Number of subjects: 36
Study 16567825 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 36
Study 12592052 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl 0.15% ophthalmic solution
Number of subjects: 0
Study 12592052 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-placebo
Number of subjects: 0
Study 10971309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 1000 microg, twice daily
Number of subjects: 25
Study 10971309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 1500 microg, twice daily
Number of subjects: 25
Study 10971309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 2500 microg, twice daily
Number of subjects: 25
Study 10971309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 1000 microg, three times daily
Number of subjects: 25
Study 10971309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 1500 microg, three times daily
Number of subjects: 25
Study 10971309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 2500 microg, three times daily
Number of subjects: 25
Study 10971309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (all doses, both regimens)
Number of subjects: 25
Study 8982131 — intervention group
Group type: EXPERIMENTAL
Intervention: poly‐L‐lactic acid screws
Number of subjects: 43
Study 8982131 — intervention group
Group type: COMPARATOR
Intervention: titanium screws
Number of subjects: 43
Study 8982131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 1443810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubated patients (more than 24 h)
Number of subjects: 20
Study 1443810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubated patients (0.5 and 0.75 ml)
Number of subjects: 20
Study 1443810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubated patients (0.25 ml)
Number of subjects: 20
Study 1443810 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 6419955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin (Prothiaden)
Number of subjects: 93
Study 6419955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 6419955 — intervention group
Group type: COMPARATOR
Intervention: Soft biteguard
Number of subjects: 93
Study 31228412 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function performance
Number of subjects: 547
Study 31228412 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory performance
Number of subjects: 547
Study 30573002 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 460
Study 30573002 — intervention group
Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 460
Study 26936861 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilization following stroke (intervention)
Number of subjects: 2104
Study 26936861 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2104
Study 25223209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.1% monotherapy (n = 23)
Number of subjects: 51
Study 25223209 — intervention group
Group type: COMPARATOR
Intervention: Bromfenac 0.1% and Betamethasone 0.1% combination therapy (n = 28)
Number of subjects: 51
Study 22708977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) in addition to unrestricted services (US)
Number of subjects: 74
Study 22708977 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted services (US)
Number of subjects: 74
Study 22708977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 74
Study 19819311 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 35
Study 19819311 — intervention group
Group type: COMPARATOR
Intervention: No-Reiki
Number of subjects: 35
Study 17679735 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 2
Study 17679735 — intervention group
Group type: COMPARATOR
Intervention: Sham biofeedback
Number of subjects: 2
Study 16222961 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 12358657 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (20 microg x kg(‐1))
Number of subjects: 109
Study 12358657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg x kg(‐1))
Number of subjects: 109
Study 12358657 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (20 microg x kg(‐1)) plus Ketamine (0.5 mg x kg(‐1))
Number of subjects: 109
Study 11385810 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer (MDPI) at peak inhaled flow rates of 90 l/min
Number of subjects: 13
Study 11385810 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer (MDPI) at peak inhaled flow rates of 60 l/min
Number of subjects: 13
Study 11385810 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer (MDPI) at peak inhaled flow rates of 45 l/min
Number of subjects: 13
Study 11385810 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler at peak inhaled flow rate of 60 l/min
Number of subjects: 13
Study 9692447 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic‐Hall prosthesis
Number of subjects: 418
Study 9692447 — intervention group
Group type: COMPARATOR
Intervention: Edwards‐Duromedics prosthesis
Number of subjects: 418
Study 9692447 — intervention group
Group type: COMPARATOR
Intervention: Björk‐Shiley prosthesis
Number of subjects: 418
Study 9692447 — intervention group
Group type: COMPARATOR
Intervention: All prostheses
Number of subjects: 418
Study 8166055 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 2614
Study 8166055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2614
Study 2451954 — intervention group
Group type: EXPERIMENTAL
Intervention: 1040 regimen (cisplatin 80 mg/m2, vincristine 1 mg, methotrexate 10 mg/m2 on days 1, 2, 3, and bleomycin 10 mg/m2 on days 1, 2, 3)
Number of subjects: 209
Study 2451954 — intervention group
Group type: COMPARATOR
Intervention: CDDP regimen (cisplatin 80 mg/m2 alone)
Number of subjects: 209
Study 2451954 — intervention group
Group type: EXPERIMENTAL
Intervention: 1040 regimen
Number of subjects: 209
Study 2451954 — intervention group
Group type: COMPARATOR
Intervention: CDDP regimen
Number of subjects: 209
Study 2451954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 209
Study 29536284 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Cognitive Behavioral Therapy (MI + CBT)
Number of subjects: 210
Study 29536284 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched education control
Number of subjects: 210
Study 28971607 — intervention group
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir 90/400 mg
Number of subjects: 42
Study 28971607 — intervention group
Group type: COMPARATOR
Intervention: emtricitabine/rilpivirine/TAF 200/25/25 mg
Number of subjects: 42
Study 26440643 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g polydextrose/d (PDX)
Number of subjects: 50
Study 26440643 — intervention group
Group type: COMPARATOR
Intervention: 0 g polydextrose/d (control)
Number of subjects: 50
Study 23980734 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol and quercetin combination (RQ)
Number of subjects: 14
Study 23980734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study 21392762 — intervention group
Group type: EXPERIMENTAL
Intervention: 4mg dexamethasone
Number of subjects: 93
Study 21392762 — intervention group
Group type: EXPERIMENTAL
Intervention: 8mg dexamethasone
Number of subjects: 93
Study 21392762 — intervention group
Group type: COMPARATOR
Intervention: 4mg ondansetron
Number of subjects: 93
Study 21392762 — intervention group
Group type: COMPARATOR
Intervention: ondansetron
Number of subjects: 93
Study 18199920 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus hydrochlorothiazide 25 mg
Number of subjects: 1181
Study 18199920 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus hydrochlorothiazide 25 mg
Number of subjects: 1181
Study 18199920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1181
Study 16775667 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 6632
Study 12750250 — intervention group
Group type: EXPERIMENTAL
Intervention: High red meat diet (420 grams)
Number of subjects: 21
Study 12750250 — intervention group
Group type: COMPARATOR
Intervention: Low meat diet (60 grams)
Number of subjects: 21